Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT04475328
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 120 participants
- Registry
-
NCT04475328
-
- Other papers using this trial's data
- Safety and efficacy of Angong Niuhuang Pills in patients with moderate-to-severe acute ischemic stroke (ANGONG TRIAL): A randomized double-blind placebo-controlled pilot clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04475328. Randomized; double masking; primary purpose treatment. Start 2020-10-01 (actual); primary completion 2022-05-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL)
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- AngongNiuhuang pill
- Intervention (Drug)
- Placebo of AngongNiuhuang pill
- Intervention (Other)
- Standard treatment
- Lead sponsor
- Peking Union Medical College Hospital
Record details
- Record id
cardio:ct-nct04475328- Content hash
43ab202cebb0ef3cb2863695fca1994ca5a8f8da752837a4ba704a3f48cf2e61